AIM: To develop a homogeneous assay for high-throughput screening (HTS) of inhibitors of phosphodiesterase 10 (PDE10). METHODS: Purified human PDE10 enzyme derived from E coli, [(3)H]-cAMP and yttrium silicate microbeads were used to develop an HTS assay based on the scintillation proximity assay (SPA) technology. This method was applied to a large-scale screening campaign against a diverse compound library and subsequent confirmation studies. Preliminary structure-activity relationship (SAR) studies were initiated through limited structural modifications of the hits. RESULTS: The IC50 value of the control compound (papaverine) assessed with the SPA approach was comparable and consistent with that reported in the literature. Signal to background (S/B) ratio and Z' factor of the assay system were evaluated to be 5.24 and 0.71, respectively. In an HTS campaign of 71 360 synthetic and natural compounds, 67 hits displayed reproducible PDE10 inhibition, of which, 8 were chosen as the scaffold for structural modifications and subsequent SAR analysis. CONCLUSION: The homogeneous PDE10 SPA assay is an efficient and robust tool to screen potential PDE10 inhibitors. Preliminary SAR studies suggest that potent PDE10 inhibitors could be identified and developed through this strategy.
AIM: To develop a homogeneous assay for high-throughput screening (HTS) of inhibitors of phosphodiesterase 10 (PDE10). METHODS: Purified human PDE10 enzyme derived from E coli, [(3)H]-cAMP and yttrium silicate microbeads were used to develop an HTS assay based on the scintillation proximity assay (SPA) technology. This method was applied to a large-scale screening campaign against a diverse compound library and subsequent confirmation studies. Preliminary structure-activity relationship (SAR) studies were initiated through limited structural modifications of the hits. RESULTS: The IC50 value of the control compound (papaverine) assessed with the SPA approach was comparable and consistent with that reported in the literature. Signal to background (S/B) ratio and Z' factor of the assay system were evaluated to be 5.24 and 0.71, respectively. In an HTS campaign of 71 360 synthetic and natural compounds, 67 hits displayed reproducible PDE10 inhibition, of which, 8 were chosen as the scaffold for structural modifications and subsequent SAR analysis. CONCLUSION: The homogeneous PDE10 SPA assay is an efficient and robust tool to screen potential PDE10 inhibitors. Preliminary SAR studies suggest that potent PDE10 inhibitors could be identified and developed through this strategy.
Authors: C J Schmidt; D S Chapin; J Cianfrogna; M L Corman; M Hajos; J F Harms; W E Hoffman; L A Lebel; S A McCarthy; F R Nelson; C Proulx-LaFrance; M J Majchrzak; A D Ramirez; K Schmidt; P A Seymour; J A Siuciak; F D Tingley; R D Williams; P R Verhoest; F S Menniti Journal: J Pharmacol Exp Ther Date: 2008-02-20 Impact factor: 4.030
Authors: Judith A Siuciak; Douglas S Chapin; John F Harms; Lorraine A Lebel; Sheryl A McCarthy; Leslie Chambers; Alka Shrikhande; Stephen Wong; Frank S Menniti; Christopher J Schmidt Journal: Neuropharmacology Date: 2006-06-15 Impact factor: 5.250
Authors: Tao Meng; Hao-ran Su; Christoph Binkert; Walter Fischli; Ling Zhou; Jing-kang Shen; Ming-wei Wang Journal: Acta Pharmacol Sin Date: 2008-04 Impact factor: 6.150
Authors: Tiffany A Coon; Alison C McKelvey; Nate M Weathington; Rahel L Birru; Travis Lear; George D Leikauf; Bill B Chen Journal: PLoS One Date: 2014-12-30 Impact factor: 3.240
Authors: Johannes R Loeffler; Monica L Fernández-Quintero; Michael Schauperl; Klaus R Liedl Journal: J Chem Inf Model Date: 2020-03-19 Impact factor: 4.956